Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 14Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Esophageal Neoplasms 12Cholangiocarcinoma 10Lung Neoplasms 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Small Cell Lung Carcinoma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Nasopharyngeal Carcinoma 6Melanoma 5Colonic Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Locally Advanced Rectal Cancer 4Hodgkin Disease 4Neoplasms 3NSCLC 3Lymphoma, Extranodal NK-T-Cell 3Glioblastoma 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2

Interventions

Sorafenib 10Magnetic Resonance Spectroscopy 10trametinib 8lenvatinib 8dabrafenib 7pembrolizumab 6Nivolumab 6Iodine-131 6Everolimus 6Sunitinib 5Paclitaxel 5vandetanib 4apatinib 4Thyrotropin Alfa 4Doxorubicin 4selpercatinib 3anlotinib 3Specimen Handling 3Radiotherapy 3Ipilimumab 3Iodine-124 3Fluorodeoxyglucose F18 3Cisplatin 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2tipifarnib 2surufatinib 2spartalizumab 2pazopanib 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Neoplasms × tislelizumab × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

West China Hospital

Phase 2 Unknown
20 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡